Trial Profile
Long-term efficacy and safety of eculizumab in Japanese patients with paroxysmal nocturnal haemoglobinuria.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2014
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 08 Jul 2014 New trial record
- 11 Aug 2013 Results published in the International Journal of Haematology.